Reflex Detection of Ciprofloxacin Resistance in Neisseria gonorrhoeae by Use of the SpeeDx ResistancePlus GC Assay
Darren YJ Lee, Melinda M Ashcroft, Eric PF Chow, Michelle Sait, Vesna De Petra, Marlene Tschaepe, Sigrid Lange, George Taiaroa, Catriona S Bradshaw, David M Whiley, Christopher K Fairley, Benjamin P Howden, Marcus Y Chen, Shivani Pasricha, Deborah A Williamson
JOURNAL OF CLINICAL MICROBIOLOGY | AMER SOC MICROBIOLOGY | Published : 2021
Resistance-guided therapy (RGT) for gonorrhea may reduce unnecessary use of broad-spectrum antibiotics. When reflexed from the Aptima Combo 2 assay, the ResistancePlus GC assay demonstrated 94.8% sensitivity and 100.0% specificity for Neisseria gonorrhoeae detection. Of the 379 concordant N. gonorrhoeae-positive samples, 86.8% were found to possess the gyrA S91F mutation, which was highly predictive for ciprofloxacin resistance and stable across 3,144 publicly available N. gonorrhoeae genomes. Our work supports the feasibility of implementing RGT for gonorrhea into routine molecular workflows.
Related Projects (3)
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by Australian National Health and Medical Research Council Emerging Leadership Investigator Grants
Awarded by NHMRC Leadership Investigator Grant
Awarded by NHMRC Practitioner Fellowship
This study was supported by a Project Grant from the National Health and Medical Research Council (NHMRC) of Australia (GNT1147735 to D.A.W., M.Y.C., E.P.F.C., and C.K.F.). E.P. F.C. and D.A. W. are supported by an Australian National Health and Medical Research Council Emerging Leadership Investigator Grants (GNT1172873 and GNT1174555, respectively). C.K.F. and C.S.B. are supported by an NHMRC Leadership Investigator Grant (GNT1172900 and GNT1173361, respectively). B.P.H. is supported by an NHMRC Practitioner Fellowship (GNT1105905).